Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Randomized, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Next Previous
Search
Trial Profile

A Phase 1b Randomized, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nepicastat (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Asieris Pharmaceuticals; Jiangsu Yahong Pharmaceutical Technology

    • Most Recent Events

    • 14 Sep 2023 According to an Asieris Pharmaceuticals media release, the company announced that it has completed the first administration of the drug in Patient with Moderately to Severely Active Ulcerative Colitis
    • 01 Sep 2023 Planned End Date changed from 1 Mar 2024 to 1 Apr 2025.
    • 01 Sep 2023 Planned primary completion date changed from 1 Feb 2024 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top